| General information |
| Database: | DB00663 |
| Objective: | With the aim to evaluate the antiproliferative effect of metformin in combination with everolimus and octreotide LAR in pancreatic welldifferentiated neuroendocrine tumor patients, a single arm, prospective, single centerphase II study was designed |
| Authors: | Pusceddu S, et al |
| Title: | Mutationtargeted therapy with sunitinib or everolimus in patients with advanced lowgrade or intermediategrade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial. |
| Journal: | Tumori. |
| Year: | 2014 |
| PMID: | 25688512 |
| Trial Design |
| Clinical Trial Id: | NCT02294006 |
| Agent: | everolimus
|
| Target: | Serine/threonineprotein kinase mTOR
|
| Cancer Type: | pancreatic cancer |
| Cancer Subtype: | advanced pancreatic neuroendocrine tumor |
| Therapy Type: | com |
| Therapeutic Combination Type: | 2 |
| Therapeutic Combination Content: | metformin + everolimus + octreotide LAR |
| Study Type: | a prospective, single center, phase II study |
| Key Patients Feature: | patients with advanced pancreatic neuroendocrine tumors |
| Biomarker: | NA |
| Biomark Analysis: | NA |
| Control Group Info: | single arm |
| Treatment Info: | everolimus in combination with octreotide LAR and metformin |
| Primary End Point: | safety and efficacy |
| Secondary End Point: | NA |
| Patients Number: | 43 |
| Trial Results |
| DLT_MTD: | NA |
| Objective Response Rate: | NA |
| Disease Control Rate: | NA |
| Median Time to Progression: | NA |
| Median PFS A vs. C: | NA |
| Median OS A vs. C: | NA |
| Adverse Event(agent arm): | NA |
| Conclusions: | NA |